On September 15, 2026, BioMarin Pharmaceutical Inc. announced the discontinuation of development for VOXZOGO in children with Noonan syndrome. The decision followed an assessment of study feasibility and the current treatment landscape, rather than safety or efficacy concerns regarding the drug. This strategic withdrawal impacts a specific pediatric indication but does not alter the company's broader pipeline or commercial operations. BioMarin Pharmaceutical Inc. operates in the biotechnology industry, focusing on the discovery, development, and commercialization of therapies for rare genetic diseases.
